 ChromaDex Corp. NASDAQ:CDXC today announced the results of multiple new preclinical studies that illustrate the multifaceted potential of Niagen nicotinamide riboside or NR in bolstering cellular health to counteract or reduce progression of numerous degenerative conditions. The proven ability of Niagen to raise NAD levels was found to contribute to positive effects in preclinical models of aging, fertility, and circadian rhythms, and in a clinical study on liver function. Several of these studies were made possible through the global ChromaDex External Research Program CERP, which offers the patented Niagen ingredient to research institutions and universities at no cost. 